OVERLAND PARK, Kan.—July 24 2024—Dr. Vince Clinical Research (DVCR), a full-service contract research organization (CRO) specializing in early-phase clinical trials, is pleased to announce “Accelerating Clinical & Drug Development Timelines with AI,”...
Our Executive Vice President of Scientific Affairs, Dr. Lynn Webster, has released a co-authored review on opioid abuse-deterrent formulations (ADFs). This comprehensive analysis delves into the effectiveness of ADFs in reducing misuse and abuse while highlighting the...
This article is featured on The Association of Clinical Research Professionals (ACRP). Bradley D. Vince, DO and Sheldon H. Preskorn, MD discuss the process of developing a new molecular entity (NME) for FDA approval and strategies for establishing early efficacy. Key...
OVERLAND PARK, Kan.—May 08 2024—Dr. Vince Clinical Research (DVCR), a full-service contract research organization (CRO), today announced the appointment of Sheldon Preskorn, M.D., as its Senior Vice President of Neuroscience. Dr. Preskorn is a world-renowned...
OVERLAND PARK, Kan.—March 13 2024—Dr. Vince Clinical Research (DVCR), a contract research organization specializing in early phase trials, announced the first dosing in a Phase II multi-center trial of SPN-820 in adults with major depressive disorder (MDD). DVCR is...
Recent Comments